Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TN-1007
- Development stage
- Preclinical
- Lead developer
- TransGenex Nanobiotech
- Modality
- Peptides
01
Overview
TN-1007 is a small peptide inhibitor developed by TransGenex Nanobiotech that specifically targets cancer stem cells (CSCs). Identified using the company's proprietary Functional in-vivo Stem cell Screening (FiSS) platform, TN-1007 is designed to inhibit signaling pathways that regulate the interactions between tumor cells and the surrounding stroma. By targeting the self-renewal and survival mechanisms of CSCs, which are often resistant to conventional therapies and responsible for tumor recurrence and metastasis, TN-1007 aims to provide a more effective treatment for various cancers. It is currently in the preclinical stage of development.
Beyond the preview
Go deeper on TN-1007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TN-1007.